Effect of Renal Impairment on the Pharmacokinetics of Pradigastat, a Novel Diacylglycerol Acyltransferase1 (DGAT1) Inhibitor

@article{Mita2015EffectOR,
  title={Effect of Renal Impairment on the Pharmacokinetics of Pradigastat, a Novel Diacylglycerol Acyltransferase1 (DGAT1) Inhibitor},
  author={Sachiko Mita and Dan Meyers and Parasar Pal and TsuHan Lin and Tapan K. Majumdar and Sam Rebello and Gangadhar Sunkara and Jin Chen},
  journal={Clinical Pharmacokinetics},
  year={2015},
  volume={54},
  pages={751-760}
}
Background and ObjectivePradigastat, a diacylglycerol acyltransferase1 inhibitor, is being developed for the treatment of familial chylomicronemia syndrome. The primary objective of this clinical study was to evaluate the effect of renal impairment on the pharmacokinetics of pradigastat.MethodsIn an open-label, parallel-group study, the single-dose (40 mg) pharmacokinetics of pradigastat were evaluated in patients with mild (n = 9), moderate (n = 10) and severe renal impairment (n = 9) compared… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 11 REFERENCES

Pharmacokinetic evaluation of escalating single intravenous and multiple oral doses of pradigastat and its absolute bioavailabilty in healthy subjects

K Kulmatycki, CD Meyers, A Crissey
  • Presented at http://abstracts.aaps.org/Verify/aaps2013/ postersubmissions/R6322.pdf. Accessed
  • 2014
VIEW 1 EXCERPT

Disposition of pradigastat (LCQ908) in humans: in vivo and in vitro investigations

A Upthagrove, H Einolf, I Hanna
  • Drug Metab Rev
  • 2013
VIEW 3 EXCERPTS